Indeed, petosemtamab has been shown to be more effective than cetuximab in various preclinical models of cancer that express both LGR5 and EGFR, in terms of inhibiting organoid growth in vitro and inhibiting xenograft tumor growth or the outgrowth of metastases in vivo (Figure 7) [47]. Here, EGFR is linked to neoplasm.